Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 5/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19080648 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL6014706 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL8528049 | 0.94 | DPP7 (0.51) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL4773570 | 0.94 | DPP7 (0.51) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL14456838 | 0.94 | DPP7 (0.51) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL8015394 | 0.92 | DPP7 (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL8526234 | 0.92 | DPP7 (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL8015391 | 0.92 | DPP7 (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL8403553 | 0.87 | DPP7 (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20366099 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| US-6039931-A | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| US-5798092-A | METAL COMPLEXES; CONTRAST AGENTS FOR MEDICAL IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-25 | — | — | US | claimed |
| US-5290794-A | Storage stable compositions | WARNER LAMBERT CO. (US) | 1994-03-01 | — | — | US | claimed |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| WO-2022022354-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3010547-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-04-21 | — | — | EP | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| EP-1944300-A2 | Prodrugs of aspartyl protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | disclosed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | disclosed |
| US-5876698-A | Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | disclosed |
| US-5733522-A | USEFUL FOR NMR DIAGNOSIS AND DIAGNOSTIC RADIOLOGY; FOR CONTRASTING THE HEPATOBILIARY SYSTEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-31 | — | — | US | disclosed |
| US-5290794-A | Storage stable compositions | WARNER LAMBERT CO. (US) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | IDO1, IDO2, CNR1 | GSR 2129/4885GNAI3 392/4885GNAO1 1639/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | GSR 1821/4885GNAI3 2650/4885GNAO1 1564/4885 |
| US-11046716-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | GSR 2887/4885GNAI3 1261/4885GNAO1 1352/4885 |
| US-20240016946-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | MRPL38, MRPS27, MRPS18A | GSR 2969/4885GNAI3 4808/4885GNAO1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.